Myrexis

Myrexis is a biopharmaceutical company based in Salt Lake City, Utah, USA. It focuses on drug development in several areas of medicine, in particular cancer therapy. It was founded in 1999 as a spin-off from Myriad Genetics[1] and was originally known as Myriad Pharmaceuticals. Richard B. Brewer was its CEO from May 2012 until his death in August 2012.[2][3]

In November 2012, the board of Myrexis announced that it planned to put the company into liquidation subject to shareholder approval.[4] In January 2013, the board reversed its decision, cancelled the liquidation, declared a special cash distribution to shareholders and appointed Jonathan M. Couchman (chairman of Xselos Holdings) as president and chief executive officer. The remaining members of the board then resigned.[5]

References

  1. ↑ Staff (2 July 2009) "Myriad Pharmaceuticals, Inc. Established As An Independent Pharmaceutical Development Company" Pharmaceutical Online, 2 July 2009. Retrieved 26 July 2014
  2. ↑ "Richard Brewer". San Francisco Chronicle. 20 August 2012. Retrieved 25 August 2012.
  3. ↑ "Myrexis Announces Death of Chief Executive Officer Richard B. Brewer, Trailblazing Biotechnology Industry Veteran and Patient Advocate". Myrexis. Archived from the original on November 5, 2012. Retrieved 15 August 2012.
  4. ↑ Tadena, Nathalie, "Myrexis Board Approves Plan to Liquidate Assets, Dissolve Company", The Wall Street Journal, 9 November 2012. Retrieved 20 January 2013 Archived August 8, 2014 at the Wayback Machine
  5. ↑ Myrexis Inc press release:"Myrexis, Inc. Announces the Cancellation of Its Upcoming Shareholder Meeting", carried by Bloomberg, 23 January 2013. Retrieved 26 July 2014
This article is issued from Wikipedia - version of the Friday, February 26, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.